Trial Information

A Multicentric Phase III Study in Patients With CLL B and C < 60 Years Not Treated: 6 Montly CHOP + 6 CHOP Every 3 Months Versus 3 Montly CHOP + Intensification and Autograft

The aim of the prospective randomized GOELAMS LLC 98 trial reported here was to compare two
therapeutic strategies in previously untreated B and C Binet stages B-CLL patients less than
60 years old. Conventional chemotherapy (Arm A) consisted of six monthly courses of CHOP,
i.e. vincristin IV 1 mg/m2 on day 1, doxorubicin IV 25 mg/m2 on day 1, cyclophosphamide (Cy)
300 mg/m2 and prednisone 40 mg/m2 both given orally from day 1 to day 5, followed by 6 CHOP
courses every other 3 months in case of response. Fludarabine (25 mg/m2 /d IV for 5
consecutive days) was used in case of non response (stable disease or progression) after 3
CHOP courses. This conventional therapy was compared to high dose therapy with autologous
CD34+ purified progenitor cell support (Arm B), used as consolidation of Complete Remission
(CR) or Very Good Partial Response (VGPR, defined by >50 % tumoral response and bone marrow
lymphocyte infiltration <30%) obtained after 3 monthly courses of CHOP. In the absence of CR
or VGPR, 3 to 6 monthly-courses of fludarabine were performed before mobilization with Cy 4
g/m2 + G-CSF administration. The conditioning regimen included TBI 12 Gy and Cy 60 mg /kg /d
for 2 days.